U.S. markets open in 1 hour 10 minutes
  • S&P Futures

    3,931.75
    +15.50 (+0.40%)
     
  • Dow Futures

    31,575.00
    +88.00 (+0.28%)
     
  • Nasdaq Futures

    12,203.25
    +62.75 (+0.52%)
     
  • Russell 2000 Futures

    1,770.00
    +8.30 (+0.47%)
     
  • Crude Oil

    108.11
    +0.49 (+0.46%)
     
  • Gold

    1,834.20
    +3.90 (+0.21%)
     
  • Silver

    21.40
    +0.27 (+1.30%)
     
  • EUR/USD

    1.0571
    +0.0012 (+0.12%)
     
  • 10-Yr Bond

    3.1250
    0.0000 (0.00%)
     
  • Vix

    28.16
    -0.89 (-3.06%)
     
  • GBP/USD

    1.2261
    -0.0009 (-0.07%)
     
  • USD/JPY

    135.4150
    +0.2450 (+0.18%)
     
  • BTC-USD

    21,292.21
    -484.83 (-2.23%)
     
  • CMC Crypto 200

    464.36
    +10.46 (+2.30%)
     
  • FTSE 100

    7,252.86
    +44.05 (+0.61%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Here's How Citi Views Amylyx Pharma

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Citi Research has raised the price target on Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) to $33 from $32, with a Buy rating.

  • It says the small market opportunity for the newly approved amyotrophic lateral sclerosis (ALS) drug in Canada (~$100 million peak) bodes well for ongoing FDA review.

  • Availability in Canada and using ALSFRS-R data as the primary basis for approval could pressure the FDA.

  • The analyst cites the political implications of an FDA rejection (CDER Director Cavazzoni's congressional testimony last year on ALS), weaknesses in the FDA's arguments on ALSFRS-R analyses in CENTAUR, and potential concerns around Canadian importation.

  • The Institute for Clinical and Economic Review (ICER) has released a new analysis to determine the ALS drug's cost-effectiveness.

  • Current analysis suggests no — for now.

  • Though Amylyx has not disclosed the price for AMX0035, branded as Albrioza in Canada, ICER pegged $169,000 per year, similar to an older ALS medicine, edaravone.

  • ICER says that the drug would not be cost-effective to the U.S. healthcare system at the above price point and far from it.

  • It notes that the price will be finalized after a public comment period in early August.

  • Price Action: AMLX shares are up 17.38% at $15.26 during the market session on the last check Tuesday.

Latest Ratings for AMLX

Date

Firm

Action

From

To

Feb 2022

Evercore ISI Group

Initiates Coverage On

Outperform

Feb 2022

HC Wainwright & Co.

Initiates Coverage On

Buy

Feb 2022

Goldman Sachs

Initiates Coverage On

Buy

View More Analyst Ratings for AMLX

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.